List of life sciences

Targeted Bioscience Launches Innovative Solutions for Biotech Industry

Retrieved on: 
Monday, December 19, 2022
Quality of life, Health, Government, Biotechnology, Algorithm, Knowledge, Data analysis, Disease, Biomarker, Precision medicine, Interest, Sales, List of life sciences

JUPITER, Fla., Dec. 19, 2022 /PRNewswire/ -- Targeted Bioscience, a leading biotechnology tools provider of innovative solutions, has quickly become known for its cutting-edge technologies and dedication to helping customers push the boundaries of what is possible in the world of biotechnology. The company, founded in 2019, offers targeted spatial profiling and precision medicine solutions tailored to the unique needs of each researcher and clinician, helping them achieve their goals faster and more effectively. Targeted Bioscience's spatial profiling portfolio enables users to identify, select and profile the complex tissue microenvironment to uncover unique biomarkers.

Key Points: 
  • The innovations developed by Targeted Bioscience will benefit science and accelerate translational and clinical research to advance precision medicine.
  • The team at Targeted Bioscience brings a wealth of knowledge and experience to the table and is committed to delivering the best possible solutions to its clients.
  • – Alan Carpino CEO, Targeted Bioscience
    In addition to its core technology offerings, Targeted Bioscience provides support services, including training, technical support, and consulting.
  • Targeted Bioscience is a leading provider of innovative solutions for the biotech industry.

IFF Announces Nourish Division Leadership Transition

Retrieved on: 
Wednesday, December 7, 2022
Cosmetics, Retail, Chemicals, Plastics, Manufacturing, Specialty, Food, Beverage, Trust, Culture, Food, Creativity, Science, Trademark, NYSE, All rights reserved, Growth, Health, International Flavors & Fragrances, Management, Perfume, IFF, Odor, Nourishing USA, List of life sciences

IFF (NYSE: IFF) today announced that Nicolas Mirzayantz, president of IFFs Nourish division, will leave the Company following a successful 34+ year tenure, effective Dec. 31, 2022.

Key Points: 
  • IFF (NYSE: IFF) today announced that Nicolas Mirzayantz, president of IFFs Nourish division, will leave the Company following a successful 34+ year tenure, effective Dec. 31, 2022.
  • Upon his departure, IFF CEO Frank Clyburn will lead IFFs current Nourish division until a replacement is named.
  • Mirzayantz had an illustrious career in which he served in critical leadership roles across the organization.
  • During his tenure, he led the division through a series of mergers and acquisitions that resulted in expanded, differentiated offerings for IFFs customers.

Global Fraud Detection and Prevention Market to Reach $118.95 Billion by 2028 at a CAGR of 24.89%

Retrieved on: 
Friday, October 28, 2022
Internet, Transport, Health, Component, Region, FDP, Hungama Digital Media Entertainment, Travel, Life, CAGR, Joint, Analysis, Adoption, Coronavirus, Real estate, App Store (iOS/iPadOS), SME, International Commission on Holocaust Era Insurance Claims, ML, Deployment, Application, Fast-moving consumer goods, COVID-19, BFSI, AI, Fraud, USD, Government, Investment, List of life sciences, Cryptocurrency, Online shopping, Pharmaceutical industry, Industry, Solution, Manufacturing, Retail, Health care, Telecom, Cloud

Global fraud detection and prevention market is valued at USD 25.1 billion in 2021, and it is estimated to surpass market size of USD 118.95 billion by 2028, at a CAGR of 24.89% over the forecast period 2022-2028.

Key Points: 
  • Global fraud detection and prevention market is valued at USD 25.1 billion in 2021, and it is estimated to surpass market size of USD 118.95 billion by 2028, at a CAGR of 24.89% over the forecast period 2022-2028.
  • Furthermore, the growing number of cyber-attacks and higher occurrences of data theft resulting in revenue loss are propelling the fraud detection and prevention market ahead.
  • Currently, the market has the opportunity to employ AI and ML in the banking sector to improve fraud detection and prevention.
  • As a result of growing cybercrime, payments fraud, insurance fraud, and other types of fraud, the outlook for the fraud detection and prevention market in the second half of 2020 and beyond boosted the adoption of fraud detection and prevention solutions.

$7.8 Billion Worldwide Gene Expression Analysis Industry to 2027 - Featuring Agilent Technologies, GE Healthcare and Illumina Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Health, Genetics, R, NGS, Toxicology, Therapy, Conditional sentence, Drug development, Prevalence, GEA, Cancer, Growth, RNA, Adoption, List of life sciences, Pacific Biosciences, Technology, RNA splicing, Protein, Industry, DNA sequencing, Research, COVID-19, Tuberculosis, Gene, Vaccine, Potash

Gene expression analysis (GEA) is the method of extracting data from a gene to investigate the behaviour of biological systems.

Key Points: 
  • Gene expression analysis (GEA) is the method of extracting data from a gene to investigate the behaviour of biological systems.
  • The data obtained from this analysis is used for the production of proteins, Ribonucleic Acid (RNA) and various microbiological products.
  • What has been the impact of COVID-19 on the global gene expression analysis market?
  • What is the structure of the global gene expression analysis market and who are the key players?

EQS-News: CHEPLAPHARM receives growth capital of EUR 550 million from two leading global investors

Retrieved on: 
Friday, October 28, 2022
EBITDA, Company, CAGR, Growth, CEO, Philosophy, Latham & Watkins, Park, General Atlantic, Deutsche Bank, AG, News, Credit Suisse, List of life sciences, J. P. Morgan, History, Security (finance), Renewable energy, Financial services, Cryptocurrency, Fine chemical, GIC, Atlantic Park station (LIRR)

The transaction will strengthen and diversify CHEPLAPHARMs financial base and help fuel the Companys growth.

Key Points: 
  • The transaction will strengthen and diversify CHEPLAPHARMs financial base and help fuel the Companys growth.
  • The investment will strengthen and diversify CHEPLAPHARM's funding as it pursues its next phase of growth.
  • Arjun Khullar, Head of GICs Integrated Strategies Group, said: GIC is looking forward to partnering with CHEPLAPHARM, a leading specialty pharma platform.
  • In 2021, CHEPLAPHARM continued its profitable growth trajectory and reached a revenue level above the 1bn mark for the first time in its history (+69% year-on-year growth to 1,082.0m).

Arthur D. Little Publishes New Report On Innovation In Life Sciences

Retrieved on: 
Thursday, October 27, 2022
Acceleration, Patient, Ecosystem, Health care, Ageing, GLOBE, ADL, Insurance, Arthur, Knowledge, Arthur D. Little, List of life sciences, Medicine, Solution, Pharmaceutical industry, Healthcare, Munich Re

LONDON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Arthur D. Little (ADL) has launched a report on current and future transformation in healthcare, and the effect these far-reaching changes will have on the life sciences and insurance sectors.

Key Points: 
  • LONDON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Arthur D. Little (ADL) has launched a report on current and future transformation in healthcare, and the effect these far-reaching changes will have on the life sciences and insurance sectors.
  • Disruptive developments such as digitization, far-reaching advances in medical technology, and the latest findings in life sciences interrelate and reinforce each other to an unprecedented extent.
  • Describing the impacts of transformation and providing insights, imperatives and key takeaways for both the insurance and life sciences industries, the report focuses on opportunities in five key areas of healthcare:
    Dr. Ulrica Sehlstedt, Managing Partner, and Global Practice Leader, Healthcare & Life Sciences at Arthur D. Little, comments: Innovation is driving a revolution at every step of the patient journey.
  • Dr. Franziska Thomas, Partner and Head of Healthcare & Life Sciences of Arthur D. Little Germany, comments: The last two years has seen an enormous acceleration in multiple areas of medicine and indeed across wider society.

Pace® Analytical Services Strengthens Presence in the Northeast, Adding Anchor Location in New Jersey

Retrieved on: 
Wednesday, October 26, 2022
Aurora, People, Acquisition, Partner, Education, Communities and Justice Directorates, Government, PFAS, CEO, Environment, APL, Biphenyl, Industry, GLOBE, Groundwater, Soil, Drinking water, Water, Polychlorinated biphenyl, Science, List of life sciences, Leonard Green & Partners, Atmosphere, Partnership, Fine chemical

"Pace is committed to providing customers with a level of convenience and connection that only laboratory partners with a local presence can provide," noted Eric Roman, Pace CEO.

Key Points: 
  • "Pace is committed to providing customers with a level of convenience and connection that only laboratory partners with a local presence can provide," noted Eric Roman, Pace CEO.
  • APL President and CEO, Robert Barrett, commented, "Like Pace, APL has been serving customers with certified laboratory services for over 40 years.
  • As part of the Pace national laboratory network, the APL location will have access to high-demand laboratory services, including a variety of air testing services .
  • "Pace continues to experience an increase in demand for testing and analysis services in the northeast, especially in New Jersey," said Greg Whitman, President of Pace Analytical Services.

ACTO Recognized as “Life Sciences Commercial Analytics and AI Trailblazer” by Everest Group

Retrieved on: 
Wednesday, October 26, 2022
IP, CEO, Risk, Organization, Artificial intelligence, Trailblazer, Software as a service, Technology, GLOBE, AI, ACTO, Efficiency, Investment, List of life sciences, Learning, Solution, Medical device

TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- ACTO , the #1 learning platform in Life Sciences,has been recognized as a Trailblazer in Life Sciences Commercial Analytics and Artificial Intelligence (AI) by Everest Group , a leading global research firm focused exclusively on strategic IT, business process, and engineering services.

Key Points: 
  • TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- ACTO , the #1 learning platform in Life Sciences,has been recognized as a Trailblazer in Life Sciences Commercial Analytics and Artificial Intelligence (AI) by Everest Group , a leading global research firm focused exclusively on strategic IT, business process, and engineering services.
  • In its Start-ups Creating Buzz in the Life Sciences Commercial Technology 2022 market report, Everest Group analyzed 47 technology start-ups offering proprietary Life Sciences Commercial Analytics & AI solutions focusing on their core capabilities and market impact.
  • "We are honored to be recognized by Everest Group for our innovation in Life Sciences software and as the only learning platform provider named a Trailblazer in this report," says Path Khanna, CEO ACTO.
  • "ACTO offers a SaaS platform specific for Life Sciences commercial stakeholder training and learning management, focusing on intelligent content management capabilities and conversational assistant for learning support, thus getting featured as a Trailblazer in Life Sciences Commercial Analytics & AI Trailblazers assessment.

Edmund Optics Announces Expanded Range of Imaging Filters With Seamless System Integration

Retrieved on: 
Tuesday, October 25, 2022
Color, R, GLOBE, List of life sciences, Catalog, OEM, Light-emitting diode, Defense, Telescopic sight, Biomedicine

BARRINGTON, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Edmund Optics, a leading global manufacturer and supplier of optical components, has expanded its extensive inventory of mounted machine vision filters.

Key Points: 
  • BARRINGTON, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Edmund Optics, a leading global manufacturer and supplier of optical components, has expanded its extensive inventory of mounted machine vision filters.
  • This product expansion includes over 350 new polarizers, color filters, and neutral density filters designed to integrate easily into a wide range of imaging systems.
  • Each filter is available in common thread types and wavelength regions for seamless pairing with Edmund Optics TECHSPEC imaging lenses.
  • The Mounted Machine Vision Filters are a line of color filters optimized for use with popular LEDs.

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Retrieved on: 
Tuesday, October 25, 2022
U.S. Securities and Exchange Commission, Perception, Time, Failure, Neuroscience, NASDAQ, RAAD, Patient, Physical disorder, Mental health, Anxiety, Private Securities Litigation Reform Act, Addiction, Ketamine, GLOBE, Annual report, Depression, Infection, NEW, Forward-looking statement, COVID-19, TRD, MADRS, Quality of life, MD, Suicidal ideation, List of life sciences, Entrepreneurship, Research, NMDA, CEO, Lists of diseases, Safety, Achievement, Program, SEC, Public expenditure, Intellectual property, Modified, Approximation error, Therapy, Security (finance), Neuropsychiatric Disease and Treatment, Â, Pharmaceutical industry

Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).

Key Points: 
  • Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).
  • atai to contextualize the upcoming Phase 2a topline results at its R&D Day today at 12 pm E.T.
  • The Phase 2a proof-of-concept trial is a randomized, double-blind, placebo-controlled study with an enrollment target of 93 TRD patients across three arms.
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.